News
ATRC
34.69
+0.87%
0.30
AtriCure’s Strong Performance and Promising Outlook Justify Buy Rating Amid Competitive Pressures
TipRanks · 1d ago
AtriCure reports preliminary results for fourth quarter
Seeking Alpha · 1d ago
AtriCure Price Target Maintained With a $40.00/Share by Needham
Dow Jones · 1d ago
Needham Reiterates Buy on AtriCure, Maintains $40 Price Target
Benzinga · 1d ago
ATRC Receives Buy Rating Due to Strong Financial Performance and Positive Growth Projections
TipRanks · 1d ago
AtriCure ups FY24 revenue view to $465.3M from $459M-$462M, consensus $460.89M
TipRanks · 1d ago
AtriCure Announces Q4 2024 Preliminary Revenue Of $124.3M, Up 17%, And FY Revenue Of $465.3M, U.S. Revenue Up 14% To $101.6M, International Revenue Increased 28% To $22.7M; Forecasted 2024 Adjusted EBITDA Is $26M-$29M And Adjusted Loss Per Share Is $0.74-$0.80
Benzinga · 2d ago
AtriCure Projects Strong Revenue Growth for 2024
TipRanks · 2d ago
Press Release: AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day
Dow Jones · 2d ago
Weekly Report: what happened at ATRC last week (0106-0110)?
Weekly Report · 2d ago
Weekly Report: what happened at ATRC last week (1230-0103)?
Weekly Report · 01/06 11:37
Weekly Report: what happened at ATRC last week (1223-1227)?
Weekly Report · 12/30/2024 11:30
Weekly Report: what happened at ATRC last week (1216-1220)?
Weekly Report · 12/23/2024 11:37
AtriCure Price Target Announced at $40.00/Share by JP Morgan
Dow Jones · 12/17/2024 12:33
AtriCure Coverage Assumed by JP Morgan at Overweight
Dow Jones · 12/17/2024 12:33
JP Morgan Assumes AtriCure at Overweight, Announces Price Target of $40
Benzinga · 12/17/2024 12:24
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Mettler-Toledo (MTD)
TipRanks · 12/17/2024 10:50
AtriCure assumed with an Overweight at JPMorgan
TipRanks · 12/17/2024 10:40
Weekly Report: what happened at ATRC last week (1209-1213)?
Weekly Report · 12/16/2024 11:38
Cracking The Code: Understanding Analyst Reviews For AtriCure
Benzinga · 12/09/2024 21:00
More
Webull provides a variety of real-time ATRC stock news. You can receive the latest news about Atricure through multiple platforms. This information may help you make smarter investment decisions.
About ATRC
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.